{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:10:29Z","timestamp":1790511029168,"version":"4.1.0"},"reference-count":68,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2014.00626","type":"journal-article","created":{"date-parts":[[2014,12,8]],"date-time":"2014-12-08T15:25:36Z","timestamp":1418052336000},"source":"Crossref","is-referenced-by-count":102,"title":["Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia"],"prefix":"10.3389","volume":"5","author":[{"given":"Nicol\u00c3\u00b2","family":"Compagno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Malipiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Agostini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2014,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjh.12067","article-title":"Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia","volume":"159","author":"Oscier","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"B2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00262-005-0015-8","article-title":"Immune defects in patients with chronic lymphocytic leukemia","volume":"55","author":"Ravandi","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"B3","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1080\/10428190400007763","article-title":"Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status","volume":"45","author":"Sinisalo","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"B4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.beha.2009.12.004","article-title":"Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches","volume":"23","author":"Morrison","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11864-001-0037-1","article-title":"Infectious complications in chronic lymphoid malignancy","volume":"2","author":"Egerer","year":"2001","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"B6","doi-asserted-by":"publisher","first-page":"CD006501","DOI":"10.1002\/14651858.CD006501.pub2","article-title":"Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation","author":"Raanani","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.tmrv.2007.01.001","article-title":"Guidelines on the use of intravenous immune globulin for hematologic conditions","volume":"21","author":"Anderson","year":"2007","journal-title":"Transfus Med Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"B9","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3324\/haematol.2013.101261","article-title":"Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients","volume":"99","author":"Compagno","year":"2014","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/cncr.22094","article-title":"The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia","volume":"107","author":"Francis","year":"2006","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1046\/j.1365-2141.2003.04497.x","article-title":"Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia","volume":"122","author":"Hensel","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"B12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","article-title":"Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin?","volume":"34","author":"Dhalla","year":"2014","journal-title":"J Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/10428194.2012.706285","article-title":"Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia","volume":"54","author":"Freeman","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"B14","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"B15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF02785839","article-title":"Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM)","volume":"16","author":"Kyrtsonis","year":"1999","journal-title":"Med Oncol"},{"issue":"4","key":"B16","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.beha.2007.10.001","article-title":"Supportive care in multiple myeloma","volume":"20","author":"Ludwig","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"issue":"8905","key":"B17","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"issue":"10","key":"B18","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00277-011-1275-3","article-title":"Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications","volume":"90","author":"Blombery","year":"2011","journal-title":"Ann Hematol"},{"issue":"1","key":"B19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","article-title":"Guidelines for supportive care in multiple myeloma 2011","volume":"154","author":"Snowden","year":"2011","journal-title":"Br J Haematol"},{"issue":"5","key":"B20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.blre.2013.07.002","article-title":"Anti-CD20 monoclonal antibodies: beyond B-cells","volume":"27","author":"Avivi","year":"2013","journal-title":"Blood Rev"},{"issue":"1\u00e2\u20ac\u201c2","key":"B21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.imlet.2013.10.005","article-title":"Complicated pathophysiology behind rituximab-induced persistent hypogammaglobulinemia","volume":"159","author":"Kano","year":"2014","journal-title":"Immunol Lett"},{"issue":"1","key":"B22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1365-2141.2009.07715.x","article-title":"Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin","volume":"146","author":"Cooper","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"B23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","article-title":"Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics","volume":"51","author":"De La Torre","year":"2012","journal-title":"Rheumatology"},{"issue":"10","key":"B24","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.autrev.2014.08.036","article-title":"Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature","volume":"13","author":"Levy","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"10","key":"B25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"QJM"},{"issue":"1","key":"B26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JCO.2005.05.282","article-title":"Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma","volume":"23","author":"Miles","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"B27","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1600-0609.2005.00552.x","article-title":"Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia","volume":"75","author":"Nishio","year":"2005","journal-title":"Eur J Haematol"},{"issue":"2","key":"B28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"B29","doi-asserted-by":"publisher","first-page":"e100324","DOI":"10.1371\/journal.pone.0100324","article-title":"Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement","volume":"9","author":"Duraisingham","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"B30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1600-0609.2008.01165.x","article-title":"Risk factors for infection in haematology patients treated with rituximab","volume":"82","author":"Kanbayashi","year":"2009","journal-title":"Eur J Haematol"},{"issue":"3","key":"B31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/jcp.2009.068940","article-title":"Does rituximab aggravate pre-existing hypogammaglobulinaemia?","volume":"63","author":"Diwakar","year":"2010","journal-title":"J Clin Pathol"},{"issue":"5","key":"B32","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaip.2014.06.003","article-title":"Rituximab and immune deficiency: case series and review of the literature","volume":"2","author":"Kaplan","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"B33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2052-1839-13-4","article-title":"Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with rituximab","volume":"13","author":"Mogensen","year":"2013","journal-title":"BMC Hematol"},{"issue":"2","key":"B34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1600-0609.2008.01174.x","article-title":"FCGR3A-158V\/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin\u00e2\u20ac\u2122s lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation","volume":"82","author":"Nishio","year":"2009","journal-title":"Eur J Haematol"},{"issue":"1","key":"B35","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"issue":"9","key":"B36","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/annonc\/mdl141","article-title":"High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication","volume":"17","author":"Cabanillas","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"B37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/sj.bmt.1704307","article-title":"Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease","volume":"33","author":"Imashuku","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"B38","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/sj.bmt.1704742","article-title":"Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia","volume":"35","author":"Lim","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"B39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/sj.bmt.1705463","article-title":"Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin\u00e2\u20ac\u2122s lymphoma","volume":"38","author":"Shortt","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"B40","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1600-0609.2006.00693.x","article-title":"Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma","volume":"77","author":"Nishio","year":"2006","journal-title":"Eur J Haematol"},{"issue":"10","key":"B41","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00277-014-2103-3","article-title":"Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study","volume":"93","author":"Witzens-Harig","year":"2014","journal-title":"Ann Hematol"},{"issue":"11","key":"B42","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/rheumatology\/ket257","article-title":"Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre","volume":"52","author":"Besada","year":"2013","journal-title":"Rheumatology"},{"issue":"5","key":"B43","doi-asserted-by":"publisher","first-page":"e37626","DOI":"10.1371\/journal.pone.0037626","article-title":"Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides","volume":"7","author":"Venhoff","year":"2012","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1471-2474-15-178","article-title":"The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease","volume":"15","author":"Marco","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"issue":"9","key":"B45","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"B46","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/ajh.23272","article-title":"Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia","volume":"87","author":"Zaja","year":"2012","journal-title":"Am J Hematol"},{"issue":"1","key":"B47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"issue":"6","key":"B48","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bmt.2014.28","article-title":"Risk factors for hypogammaglobulinemia after allo-SCT","volume":"49","author":"Arai","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"B49","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/sj.bmt.1705892","article-title":"Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival","volume":"41","author":"Norlin","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"B50","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"B51","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1399-3046.2012.01783.x","article-title":"Subcutaneous IgG replacement after pediatric SCT","volume":"16","author":"Sundin","year":"2012","journal-title":"Pediatr Transplant"},{"issue":"10","key":"B52","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1111\/ajt.12401","article-title":"What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis","volume":"13","author":"Florescu","year":"2013","journal-title":"Am J Transplant"},{"issue":"3","key":"B53","doi-asserted-by":"publisher","first-page":"E277","DOI":"10.1111\/j.1399-0012.2012.01653.x","article-title":"Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post-transplant antibody deficiency and severe infections","volume":"26","author":"Carbone","year":"2012","journal-title":"Clin Transplant"},{"issue":"Suppl 2","key":"B54","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1034\/j.1399-3062.2001.00008.x","article-title":"Hypogammaglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes","volume":"3","author":"Yamani","year":"2001","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"B55","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.intimp.2013.02.021","article-title":"Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients","volume":"15","author":"Shankar","year":"2013","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"B56","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/039463201402700220","article-title":"Safety and infectious prophylaxis of intravenous immunoglobulin in elderly patients with membranous nephropathy","volume":"27","author":"Molinaro","year":"2014","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"4","key":"B57","doi-asserted-by":"crossref","first-page":"E301","DOI":"10.25011\/cim.v32i4.6622","article-title":"Immunological disturbances in Good\u00e2\u20ac\u2122s syndrome","volume":"32","author":"Fijolek","year":"2009","journal-title":"Clin Invest Med"},{"key":"B58","article-title":"Intravenous immunoglobulin replacement therapy to prevent pulmonary infection in a patient with Good\u00e2\u20ac\u2122s syndrome","volume-title":"J Microbiol Immunol Infect","author":"Wang","year":"2012"},{"issue":"4","key":"B59","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.iac.2008.06.001","article-title":"Intravenous gammaglobulin treatment in HIV-1 infection","volume":"28","author":"Deener","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"B60","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3109\/08830185.2010.529975","article-title":"Immunomodulatory effects of intravenous immunoglobulins (IVIGs) in HIV-1 disease: a systematic review","volume":"30","author":"Pastori","year":"2011","journal-title":"Int Rev Immunol"},{"issue":"2","key":"B61","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM199107113250201","article-title":"Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection","volume":"325","author":"The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group","year":"1991","journal-title":"N Engl J Med"},{"issue":"4","key":"B62","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.iac.2008.07.002","article-title":"Subcutaneous administration of IgG","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"B63","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.iac.2008.01.008","article-title":"Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"B64","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00063030-200721020-00005","article-title":"Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route","volume":"21","author":"Gardulf","year":"2007","journal-title":"BioDrugs"},{"issue":"1","key":"B65","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.clim.2007.06.009","article-title":"Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy","volume":"126","author":"Gardulf","year":"2008","journal-title":"Clin Immunol"},{"issue":"2","key":"B66","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","article-title":"Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies \u00e2\u20ac\u201c a prospective, multi-national study","volume":"26","author":"Gardulf","year":"2006","journal-title":"J Clin Immunol"},{"issue":"3","key":"B67","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J Clin Immunol"},{"issue":"6","key":"B68","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s10875-011-9588-5","article-title":"Efficacy and safety of subcutaneous vivaglobin(R) replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study","volume":"31","author":"Borte","year":"2011","journal-title":"J Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T07:15:04Z","timestamp":1566112504000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2014.00626\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,8]]},"references-count":68,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2014.00626","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,8]]}}}